All-Amgen Denosumab Raises Hopes; Proof-Of-Concept Peek Due At ASCO
Executive Summary
If Amgen's denosumab works as well in Phase III as investors hope, the bone-building drug could become not only a bottom-line savior after the much-publicized trouble with erythropoietin stimulating agents, but could also become a matter of significant pride for its developers
You may also be interested in...
FDA Panel Votes To Limit ESA Cancer Use To Metastatic Patients
Following the recommendations of its Oncologic Drugs Advisory Committee, FDA's next step in ensuring the safe use of erythropoiesis-stimulating agents will be to determine how best to narrow the approved indication for anemia treatment in the cancer setting
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
With a would-be competitor from Discovery Labs stalled at FDA, approved lung surfactant Curosurf sits at the center of equity, cash tie-up.